标题
DNA Hypomethylating Drugs in Cancer Therapy
作者
关键词
-
出版物
Cold Spring Harbor Perspectives in Medicine
Volume 7, Issue 5, Pages a026948
出版商
Cold Spring Harbor Laboratory
发表日期
2017-02-04
DOI
10.1101/cshperspect.a026948
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells
- (2015) Anderly C. Chueh et al. ANTIOXIDANTS & REDOX SIGNALING
- A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
- (2015) Helai P. Mohammad et al. CANCER CELL
- A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine
- (2015) Edward M. Newman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia
- (2015) J. Yamazaki et al. CANCER RESEARCH
- DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
- (2015) David Roulois et al. CELL
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- Minimal role of base excision repair in TET-induced global DNA demethylation in HEK293T cells
- (2015) Chunlei Jin et al. Epigenetics
- Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
- (2015) Kristen Meldi et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
- (2015) Jean-Pierre J Issa et al. LANCET ONCOLOGY
- Epigenetic synergy between decitabine and platinum derivatives
- (2015) Taichun Qin et al. Clinical Epigenetics
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
- (2015) Huili Li et al. Oncotarget
- TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
- (2014) R. Bejar et al. BLOOD
- A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
- (2014) R M Glasspool et al. BRITISH JOURNAL OF CANCER
- Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
- (2014) Jean-Pierre Issa et al. CANCER
- Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
- (2014) Xiaojing Yang et al. CANCER CELL
- Predicting response to epigenetic therapy
- (2014) Marianne B. Treppendahl et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical development of demethylating agents in hematology
- (2014) Shyamala C. Navada et al. JOURNAL OF CLINICAL INVESTIGATION
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
- (2014) Thomas Prebet et al. JOURNAL OF CLINICAL ONCOLOGY
- Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
- (2014) K. Odunsi et al. Cancer Immunology Research
- Genomic impact of transient low-dose decitabine treatment on primary AML cells
- (2013) J. M. Klco et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- IDH1 and IDH2 Mutations in Gliomas
- (2013) Adam L. Cohen et al. Current Neurology and Neuroscience Reports
- DNA methylation and nucleosome occupancy regulate the cancer germline antigen geneMAGEA11
- (2013) Smitha R James et al. Epigenetics
- Dynamic DNA methylation across diverse human cell lines and tissues
- (2013) K. E. Varley et al. GENOME RESEARCH
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
- (2013) F Traina et al. LEUKEMIA
- DNA methylation: roles in mammalian development
- (2013) Zachary D. Smith et al. NATURE REVIEWS GENETICS
- Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer
- (2013) Christoph Plass et al. NATURE REVIEWS GENETICS
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Functional DNA demethylation is accompanied by chromatin accessibility
- (2013) Kurinji Pandiyan et al. NUCLEIC ACIDS RESEARCH
- Concise Drug Review: Azacitidine and Decitabine
- (2013) E. J. B. Derissen et al. ONCOLOGIST
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
- (2012) M. A. Sekeres et al. BLOOD
- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
- (2012) W. Blum et al. BLOOD
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
- (2012) Hsing-Chen Tsai et al. CANCER CELL
- DNA Methylation Does Not Stably Lock Gene Expression but Instead Serves as a Molecular Mark for Gene Silencing Memory
- (2012) N. J.- M. Raynal et al. CANCER RESEARCH
- Epigenetic Resensitization to Platinum in Ovarian Cancer
- (2012) D. Matei et al. CANCER RESEARCH
- Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique
- (2012) Jaroslav Jelinek et al. Epigenetics
- TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group
- (2012) Verena I. Gaidzik et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine
- (2012) Peter L. Greenberg et al. LEUKEMIA & LYMPHOMA
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia
- (2012) Marta Kulis et al. NATURE GENETICS
- Functions of DNA methylation: islands, start sites, gene bodies and beyond
- (2012) Peter A. Jones NATURE REVIEWS GENETICS
- HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
- (2011) M. Kalac et al. BLOOD
- Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
- (2011) T. Braun et al. BLOOD
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- DNA methylation: TET proteins—guardians of CpG islands?
- (2011) Kristine Williams et al. EMBO REPORTS
- Genome-scale analysis of aberrant DNA methylation in colorectal cancer
- (2011) T. Hinoue et al. GENOME RESEARCH
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine
- (2011) M T Voso et al. LEUKEMIA
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
- (2011) Taichun Qin et al. PLoS One
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
- (2011) R. A. Juergens et al. Cancer Discovery
- Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML
- (2010) T. A. Paul et al. BLOOD
- Cancer Epigenetics
- (2010) Rodolphe Taby et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- Chromatin Remodeling Is Required for Gene Reactivation after Decitabine-Mediated DNA Hypomethylation
- (2010) J. Si et al. CANCER RESEARCH
- Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
- (2010) Sean J. Whittaker et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term Stability of Demethylation after Transient Exposure to 5-Aza-2'-Deoxycytidine Correlates with Sustained RNA Polymerase II Occupancy
- (2010) J. D. Kagey et al. MOLECULAR CANCER RESEARCH
- Delivery of 5-Azacytidine to Human Cancer Cells by Elaidic Acid Esterification Increases Therapeutic Drug Efficacy
- (2010) B. Brueckner et al. MOLECULAR CANCER THERAPEUTICS
- Nanaomycin A Selectively Inhibits DNMT3B and Reactivates Silenced Tumor Suppressor Genes in Human Cancer Cells
- (2010) D. Kuck et al. MOLECULAR CANCER THERAPEUTICS
- Conserved role of intragenic DNA methylation in regulating alternative promoters
- (2010) Alika K. Maunakea et al. NATURE
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Mechanistic Insights on the Inhibition of C5 DNA Methyltransferases by Zebularine
- (2010) Christine Champion et al. PLoS One
- DNMT3L Modulates Significant and Distinct Flanking Sequence Preference for DNA Methylation by DNMT3A and DNMT3B In Vivo
- (2010) Bethany L. Wienholz et al. PLoS Genetics
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
- (2009) O. Abdel-Wahab et al. BLOOD
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
- (2009) Melissa J LaBonte et al. BMC Medical Genomics
- A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors
- (2009) J. Lin et al. CLINICAL CANCER RESEARCH
- Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas
- (2009) D. J. Stewart et al. CLINICAL CANCER RESEARCH
- Targeting DNA Methylation
- (2009) J.-P. J. Issa et al. CLINICAL CANCER RESEARCH
- Three DNA Methylation Epigenotypes in Human Colorectal Cancer
- (2009) K. Yagi et al. CLINICAL CANCER RESEARCH
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Acquired mutations in TET2 are common in myelodysplastic syndromes
- (2009) Saskia M C Langemeijer et al. NATURE GENETICS
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
- (2008) T. Qin et al. BLOOD
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
- (2008) Gautam Borthakur et al. LEUKEMIA & LYMPHOMA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started